⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22468654 | 0.97 | HTR2C (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL22612783 | 0.85 | GABRP (0.33) | — | |
| SCHEMBL22488209 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL22468580 | 0.78 | — | — | |
| SCHEMBL13451931 | 0.75 | HTR2C (0.43) | — | |
| SCHEMBL22488553 | 0.75 | TSHR (0.39) | — | |
| SCHEMBL10050843 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL27629469 | 0.73 | HTR2C (0.45) | — | |
| Hydrochloric Acid SCHEMBL22468585 | 0.73 | BLM (0.41) | — | |
| SCHEMBL22488312 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11407737-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20210300904-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-09-30 | — | — | US | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| WO-2021081375-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2020227020-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| CN-106543065-B | A kind of 4- trifluoromethyl -2,4- bis- replaces -2,5- dihydro pyrrole derivates and its preparation method and application | 华东师范大学 | 2019-06-11 | — | — | CN | disclosed |
| CN-106543065-A | 2,4 2 replacement of a kind of 4 trifluoromethyl, 2,5 dihydro pyrrole derivates and its preparation method and application | 华东师范大学 | 2017-03-29 | — | — | CN | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |